Purpose: Questions are being raised regarding the cost of particle therapy (PT), and with them criticism that PT is too expensive to allow the expected gain in effectiveness. This paper aims to get more insight in the cost and cost-effectiveness of particle therapy and to discuss a future strategy that allows for critical assessment of this health technology. Material and methods: A systematic literature review based on an earlier published comprehensive review was performed and updated until June 1st 2008. Besides, current business plans of PT projects were examined. Additionally, results retrieved from a cost-simulation tool developed under auspice of the ENLIGHT were discussed. Results: The current literature on cost-effectiveness of PT is scarce, non-comparable, and largely not performed according to standard health technology assessment criteria. Besides, different perspectives for cost evaluations have been used, making it difficult to compare and to determine the relative impact in terms of costs for this new treatment modality. Conclusions: Evidence on the cost-effectiveness of PT is scarce. Adequate reimbursement is necessary to support such innovative yet costly treatments. For now, model-based economic evaluations performed at least from a health care perspective may help us to gain evidence-based insight into cost-effectiveness. (c) 2008 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 89 (2008) 127-134.
机构:
Istanbul Univ, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, TurkeyIstanbul Univ, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkey
Eskazan, Ahmet Emre
Soysal, Teoman
论文数: 0引用数: 0
h-index: 0
机构:
Istanbul Univ, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, TurkeyIstanbul Univ, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkey
机构:
Tufts Univ, Sch Med, Ctr Study Drug Dev, Boston, MA 02111 USATufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
Wilson, Andrew W.
Neumann, Peter J.
论文数: 0引用数: 0
h-index: 0
机构:
Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USATufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
机构:
Department of Neurology, University of Rochester School of Medicine, RochesterDepartment of Neurology, University of Rochester School of Medicine, Rochester
Noyes K.
Holloway R.G.
论文数: 0引用数: 0
h-index: 0
机构:
Department of Neurology, University of Rochester School of Medicine, RochesterDepartment of Neurology, University of Rochester School of Medicine, Rochester